Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

Maria E. Figueroa, Lucy Skrabanek, Yushan Li, Anchalee Jiemjit, Tamer E. Fandy, Elisabeth Paietta, Hugo Fernandez, Martin S. Tallman, John M. Greally, Hetty Carraway, Jonathan D. Licht, Steven D. Gore, Ari Melnick

Blood (2009) 114 (16): 3448–3458.

https://doi.org/10.1182/blood-2009-01-200519

Published: 2009

Includes: Supplemental data

Journal Articles

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

Blood (2009) 114 (13): 2764–2773.

https://doi.org/10.1182/blood-2009-02-203547

Published: 2009

Includes: Supplemental data

Journal Articles

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

Ivana Gojo, Anchalee Jiemjit, Jane B. Trepel, Alex Sparreboom, William D. Figg, Sandra Rollins, Michael L. Tidwell, Jacqueline Greer, Eun Joo Chung, Min-Jung Lee, Steven D. Gore, Edward A. Sausville, James Zwiebel, Judith E. Karp

Blood (2006) 109 (7): 2781–2790.

https://doi.org/10.1182/blood-2006-05-021873

Published: 2006

Journal Articles

Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.

Steven D. Gore, MD, Anchalee Jiemjit, MS, Lewis B. Silverman, MD, Timothy Aucott, Stephen Baylin, MD, Hetty Carraway, MD, Tianna Dauses, BSN, Tamer Fandy, PhD, James Herman, MD, Judith E. Karp, MD, Jonathan D. Licht, MD, Anthony J. Murgo, MD, Rosalie Odchimar-Reissig, BSN, B. Douglas Smith, MD, James A. Zwiebel, MD, Elizabeth Sugar, PhD

Blood (2006) 108 (11): 517.

https://doi.org/10.1182/blood.V108.11.517.517

Published: 2006

Journal Articles

Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.

Steven D. Gore, MD, Stephen B. Baylin, MD, Tianna Dauses, RN, Michael R. Grever, MD, Anchalee Jiemjit, MS, Jasper Manning, MS, Carole B. Miller, MD, Anthony J. Murgo, MD, James A. Zwiebel, MD, James G. Herman, MD

Blood (2004) 104 (11): 469.

https://doi.org/10.1182/blood.V104.11.469.469

Published: 2004

NARROW

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.

Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.

Email alerts

ASH Publications

American Society of Hematology

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.

Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only